期刊
THROMBOSIS AND HAEMOSTASIS
卷 111, 期 6, 页码 1167-1176出版社
GEORG THIEME VERLAG KG
DOI: 10.1160/TH14-03-0231
关键词
Atrial fibrillation; screening; stroke prevention; cost-effectiveness; anticoagulation
资金
- Bristol-Myers Squibb/Pfizer
- Bayer
- Career Development and Future Leader Fellowship
- NHMRC
- National Heart Foundation [APP1061793]
- National Heart Foundation Postgraduate Scholarship [PP12S6990]
- Boehringer Ingelheim
Atrial fibrillation (AF) causes a third of all strokes, but often goes undetected before stroke. Identification of unknown AF in the community and subsequent anti-thrombotic treatment could reduce stroke burden. We investigated community screening for unknown AF using an iPhone electrocardiogram (iECG) in pharmacies, and determined the cost-effectiveness of this strategy. Pharmacists performed pulse palpation and iECG recordings, with cardiologist iECG over-reading. General practitioner review/12-lead ECG was facilitated for suspected new AF. An automated AF algorithm was retrospectively applied to collected iECGs. Cost-effectiveness analysis incorporated costs of iECG screening, and treatment/outcome data from a United Kingdom cohort of 5,555 patients with incidentally detected asymptomatic AF. A total of 1,000 pharmacy customers aged >= 65 years (mean 76 +/- 7 years; 44% male) were screened. Newly identified AF was found in 1.5% (95% Cl, 0.8-2.5%); mean age 79 +/- 6 years; all had CHA(2)DS(2)-VASc score >= 2. AF prevalence was 6.7% (67/1,000). The automated iECG algorithm showed 98.5% (Cl, 92-100%) sensitivity for AF detection and 91.4% (Cl, 89-93%) specificity. The incremental cost-effectiveness ratio of extending iECG screening into the community, based on 55% warfarin prescription adherence, would be $AUD5,988 ((sic),142; $USD4,066) per Quality Adjusted Life Year gained and $AUD30,481 ((sic)15,993; $USD20,695) for preventing one stroke. Sensitivity analysis indicated cost-effectiveness improved with increased treatment adherence. Screening with iECG in pharmacies with an automated algorithm is both feasible and cost-effective. The high and largely preventable stroke/thromboembolism risk of those with newly identified AF highlights the likely benefits of community AF screening. Guideline recommendation of community iECG AF screening should be considered.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据